Document is current
Any future updates will be listed below
-
Authors
Vandermeulen, Lina
Geric, Ivana
Fumagalli, Laura
Kreir, Mohamed
Lu, Ashley
Nonneman, Annelies
Premereur, Jessie
Wolfs, Leen
Policarpo, Rafaela
Fattorelli, Nicola
De Bondt, An
Van Den Wyngaert, Ilse
Asselbergh, Bob
Fiers, Mark
De Strooper, Bart
d’Ydewalle, Constantin
Mancuso, Renzo https://orcid.org/0000-0002-7046-3348
-
Funding
Funding for this research was provided by:
Agentschap Innoveren en Ondernemen (HBC.2018.2290)
- License Information
-
More Information
Article History
Received: 24 November 2023
Accepted: 17 March 2024
First Online: 24 April 2024
Declarations
:
: All authors discussed the results, commented on the manuscript and consented publication.
: L.V., A.N., M.K., A.D.B., I.V.D.W. and C.D.Y. are employees of Janssen Pharmaceutica, pharmaceutical companies of Johnson&Johnson. I.G. and A.L. are employees of Muna Therapeutics since October 2022. B.D.S. is or has been a consultant for Eli Lilly, Biogen, Janssen Pharmaceutica, Eisai, AbbVie and other companies. B.D.S is also a scientific founder of Augustine Therapeutics and a scientific founder and stockholder of Muna Therapeutics. R.M. has scientific collaborations with Janssen Pharmaceutica, Alector and Nodthera and is consultant of Sanofi.
